| Page | 1 | ٥f | A |
|------|---|----|----|
| rage | ı | Οī | 70 |

| | | | | | | | | | | | | · | Page 1 o | Ι]Δ, | |
|----------------------------------|-----------|---------|-------|--------|--|-------|-------|--|--|--------------------------|--|--|--|-----------|--|
| | | | | | | | | | epartment of Commerce and Trademark Office Atty. Docket No. 62812-AB/JPW/GJG/JBC | | | Serial No. Not Yet Known | | | |
| | I | NF(| | | | | | | SURE CIT | | Applicants: Mitchell Shirvan et al. | | | | |
| (Use several sheets if | | | | | | | | ets i | i necessary) | | Filing Date Herewith | | Group | | |
| | | _ | | | | | | | U.S. PA | TENT DOCUMEN | TS | | | | |
| Examiner Document Number Initial | | | | | | | | | Date | Name | Class | Subclass | Subclass Filing Date if Appropriate | | |
| /SH/ | | 4 | 6 | 3 | 9 | 4 | 6 | 8 | 1/27/87 | Roncucci et al.; | | | | | |
| | | 4 | 6 | 9 | 9 | 9 | 2 | 7 | 10/13/87 | Deboeck; | | | | | |
| | | 4 | 9 | 1 | 3 | 9 | 0 | 6 | 4/3/90 | Friedman et al.; | 1 | | | | |
| | | 4 | 3 | 0 | 1 | 1 | 7 | 6 | 11/17/81 | Grabowski et al.; | | | | | |
| | | 5 | 1 | 6 | 9 | 6 | 4 | 2 | 12/8/92 | Brinker et al.; | | | 1 | | |
| | + | 5 | 5 | 8 | 5 | 3 | 5 | 8 | 12/17/96 | Bialer; | | | - | | |
| | +- | 5 | 9 | 4 | 5 | 4 | 1 | 6 | 8/31/99 | Shannon et al.: | | | | | |
| | | 5 | 7 | 6 | 6 | 0 | 6 | 7 | 6/2/98 | Shank et al.; | | | + | | |
| | | 6 | 2 | 8 | 7 | 5 | 9 | 8 | 9/11/01 | Ayer et al; | - | | | | |
| | | 6 | 3 | 1 | 9 | 9 | 0 | 3 | 1/20/01 | Carrazana et al.; | | | | | |
| | | 6 | 2 | 5 | | 9 | 4 | 6 | 6/26/01 | Vinikova et al.; | | | | | |
| Ψ | | 6 | 2 | 6 | 8 | 3 | 9 | 6 | 7/31/01 | Nau et al.; | | | | | |
| | | | ۰ | | <u>. </u> | | | ــــــــــــــــــــــــــــــــــــــ | FOREICN | PATENT DOCUM | LENTES | <u></u> | 1 | | |
| | | Do | cun | nent | Nu | mb | er | - | Date | Country | Class | Subclas | s Translati | ion | |
| | · | | | | | | | | | Yes | No | | | | |
| /SH/ | BL | 0 | 8 | 8 | 5 | 3 | 0 | 3 | 9/19/80 | BL; | | | 1 | | |
| | CN | 1 | 2 | 0 | 8 | 2 | 3 | 0 | 7/22/86 | CN; | <u> </u> | | | | |
| | EP | 0 | 0 | 4 | 6 | 7 | 0 | 7 | 3/3/82 | EPO; | | | | | |
| | EP | 0 | 2 | 5 | 0 | 9 | 9 | 7 | 7/1/88 | EPO; | | | + | | |
| | EP | 0 | 4 | 4 | 2 | 0 | + | 2 | 8/21/91 | EPO; | | | | + | |
| | EP | 0 | 6 | 5 | 9 | 1 | 7 | 4 | 10/2/99 | EPO; | · | | | | |
| | FR | 2 | 5 | 3 | 1 | 9 | 5 | 0 | 8/19/83 | FR; | 1 | | | | |
| | GB | 2 | 1 | 2 | 6 | 2 | 2 | 4 | 3/21/84 | GB; | T | | | | |
| ΔL | SU | 0 | 9 | 8 | 8 | 1 | 8 | 8 | 1/7/83 | SU; | | | | | |
| | wo | 8 | 8 | 0 | 1 | 8 | 6 | 1 | 3/24/88 | PCT; | | | <u></u> _ | | |
| | | | | TH | ER | DO | CU | ME | NTS (Inclu | ding Author, Title, l | Date, Pertinent | Pages, Etc.) | | | |
| | | Bia | | | | | | | | | nacokinet., 1991, 2 | | ; | | |
| EXAMINER /San Ming Hui/ | | | | | | | | <u></u> | DATE CONS | SIDERED 11/15 | 5/2007 | | | | |
| *EXAMIN | ER: Init | Lial if | Citat | ion c | onsid | lered | whe | ther | or not citation is | s in conformance with MP | EP 600: Denu line 1 | hemiah citation if | not in confe- | nance and | |
| not conside | red. Incl | ude c | ору | of thi | s for | m wi | th ne | xt co | mmunication to | applicant. | Li 603. Diaw iliic u | acegn cianon ii | not in Comon | HANCE AND | |

Applicants: Mitchell Shirvan et al. Serial No.: Not Yet Known

Filed: Herewith Exhibit A

age 2 of

| Patent and Trademark Office INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) Applicants: | | | | | | | | | | | | | Page 2 of | - |
|--|--|--|---|------------------------|--------|-------|----------|---------------|-----------------------------|------------------------------|----------------|------------------|--|--------------|
| (Use several sheets if necessary) Mitchell Shirvan et al. Filing Date: Group Herewith | | | | | | | | | | | 62812- | | | |
| U.S. PATENT DOCUMENTS Document Number | | | INFO | | | | | | | | | van et al. | | |
| Examiner Initial Document Number Date Name Class Subclass Filing Date Appropriate | (SSS SS - ST SI SILVER | | | | | | | ٠ | | | | | Group | |
| FOREIGN PATENT DOCUMENTS Shape Sh | | | | | | | | | U.S. PAT | TENT DOCUMENTS | | | | |
| Document Number Date Country Class Subclass Yes No /SH WO 9 5 0 1 9 5 6 1/19/95 PCT(Exhibit 2); | Examiner Initial | | | Docum | nent ! | Num | ber | , | | | Class | | | |
| Document Number Date Country Class Subclass Yes No /SH WO 9 5 0 1 9 5 6 1/19/95 PCT(Exhibit 2); | | +- | +-+- | - | ┾ | ₩. | ┼ | ┼ | | | | | | |
| Document Number Date Country Class Subclass Yes No /SH WO 9 5 0 1 9 5 6 1/19/95 PCT(Exhibit 2); | | + | ++ | + | ╁ | - | \vdash | ╁ | | | | | | |
| Document Number Date Country Class Subclass Yes No /SH WO 9 5 0 1 9 5 6 1/19/95 PCT(Exhibit 2); | | | +-+- | \top | + | T | <u> </u> | ┢ | <u> </u> | | <u> </u> | | | |
| Document Number Date Country Class Subclass Yes No /SH WO 9 5 0 1 9 5 6 1/19/95 PCT(Exhibit 2); | | | | | | 1 | | \vdash | | | | | | |
| Document Number Date Country Class Subclass Yes No /SH WO 9 5 0 1 9 5 6 1/19/95 PCT(Exhibit 2); | | | | | | | | | | | | | | |
| Document Number Date Country Class Subclass Yes No /SH WO 9 5 0 1 9 5 6 1/19/95 PCT(Exhibit 2); | | | | | | | | | | | | | | |
| SH | | | | | | | | | FOREIGN | PATENT DOCUMENTS | s | | | |
| SH | | | | | | | | | | | | | | |
| SH/ IE 0 0 5 2 4 1 5 10/28/87 IE (Exhibit 3); | | | | _ | Nu | _ | | | | | Class | Subclass | Yes | No |
| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) /SH/ Re-examination certificate of U.S. Patent No. 4,913,906 (Exhibit 1); Bialer et al., "Pharmacokinetics of a Valpromide Isomer, Valnoctamide, in Healthy Subjects", Eur. J. Clin. Pharmacol 1990,38:289-291; Buzzi et al., "The Antimigraine Drug, Sumatriptan (GR43175), Selectively Blocks Neurogenic Plasma Extravasation from Blood Vessels in Dura Mater", Brit. J. Pharmacol., 1990, 99: 202-206; Granneman et al., "Aspects of the Metabolism of Valproic Acid", Chem. Abstracts, 1984, 101(17): 143458; Granneman, "Aspects of the Metabolism of Valproic Acid", Xenobiotica, 1984, 14(5): 375-387; Hadad et al., "Pharmacokinetic Analysis of Ester Prodrugs of Valproic Acid," J. Pharm. Sci., 1992, 81(10): 1047-1050; Hansen, H.C., Southern Medical Journal (1999) 92(7):642-649; Haj-Yehia et al., "Structure-Pharmacokinetic Relationships in a Series of Valpromide Derivatives with Antiepilepi Activity", Pharm. Research, 1989, 6(8): 683-689; Kim et al., "An Experimental Model for Peripheral Neuropathy Produced by Segmental Spinal Nerve Ligation in the Rat J.M., Pain, 1992, 50: 355-363; March, Advanced Organic Chemistry, 3 rd Edition, 1985, 354-355,368,377-379; McQuay, H. et al., BMJ (1995) 311: 1047-1052; Magnus, L., Epitepsia (1999) 40(Suppl. 6): S66-S72; Zakrzewska, J.M. et al., Pain (1997) 73: 233-230; Yu et al., "Simultaneous Delivery of Valproic Acid and Glycine to the Brain", Neuropath., 1991, 15(1): 37; "Milacemide", Drugs of the Future, 1984, 9(8): 587-588; and "Milacemide", Drugs of the Future, 1991, 16(8): 775. EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in | /SH/ | wc | 9 5 | 0 | 1 | 9 | 5 | 6 | 1/19/95 | PCT(Exhibit 2); | | ļ | | |
| Re-examination certificate of U.S. Patent No. 4,913,906 (Exhibit 1); Bialer et al., "Pharmacokinetics of a Valpromide Isomer, Valnoctamide, in Healthy Subjects", Eur. J. Clin. Pharmacol 1990,38:289-291; Buzzi et al., "The Antimigraine Drug, Sumatriptan (GR43175), Selectively Blocks Neurogenic Plasma Extravasation from Blood Vessels in Dura Mater", Brit. J. Pharmacol., 1990, 99: 202-206; Granneman et al., "Aspects of the Metabolism of Valproic Acid", Chem. Abstracts, 1984, 101(17): 143458; Granneman, "Aspects of the Metabolism of Valproic Acid", Kenobiotica, 1984, 14(5): 375-387; Hadad et al., "Pharmacokinetic Analysis of Ester Prodrugs of Valproic Acid," J. Pharm. Sci., 1992, 81(10): 1047-1050; Hansen, H.C., Southern Medical Journal (1999) 92(7):642-649; Haj-Yehia et al., "Structure-Pharmacokinetic Relationships in a Series of Valpromide Derivatives with Antiepilepi Activity", Pharm. Research, 1989, 6(8): 683-689; Kim et al., "An Experimental Model for Peripheral Neuropathy Produced by Segmental Spinal Nerve Ligation in the Rat J.M., Pain, 1992, 50: 355-363; March, Advanced Organic Chemistry, 3rd Edition, 1985, 354-355,368,377-379; McQuay, H. et al., BMJ (1995) 311: 1047-1052; Zakrzewska, J.M. et al., Pain (1997) 73: 233-230; Yu et al., "Simultaneous Delivery of Valproic Acid and Glycine to the Brain", Neuropath., 1991, 15(1): 37; "Milacemide", Drugs of the Future, 1984, 9(8): 587-588; and "Milacemide", Drugs of the Future, 1984, 9(8): 775. EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in | /SH/ | ΙE | 0 0 | 5 | 2 | 4 | 1 | 5 | 10/28/87 | IE (Exhibit 3); | 1 | | | |
| Re-examination certificate of U.S. Patent No. 4,913,906 (Exhibit 1); Bialer et al., "Pharmacokinetics of a Valpromide Isomer, Valnoctamide, in Healthy Subjects", Eur. J. Clin. Pharmacol 1990,38:289-291; Buzzi et al., "The Antimigraine Drug, Sumatriptan (GR43175), Selectively Blocks Neurogenic Plasma Extravasation from Blood Vessels in Dura Mater", Brit. J. Pharmacol., 1990, 99: 202-206; Granneman et al., "Aspects of the Metabolism of Valproic Acid", Chem. Abstracts, 1984, 101(17): 143458; Granneman, "Aspects of the Metabolism of Valproic Acid", Kenobiotica, 1984, 14(5): 375-387; Hadad et al., "Pharmacokinetic Analysis of Ester Prodrugs of Valproic Acid," J. Pharm. Sci., 1992, 81(10): 1047-1050; Hansen, H.C., Southern Medical Journal (1999) 92(7):642-649; Haj-Yehia et al., "Structure-Pharmacokinetic Relationships in a Series of Valpromide Derivatives with Antiepilepi Activity", Pharm. Research, 1989, 6(8): 683-689; Kim et al., "An Experimental Model for Peripheral Neuropathy Produced by Segmental Spinal Nerve Ligation in the Rat J.M., Pain, 1992, 50: 355-363; March, Advanced Organic Chemistry, 3rd Edition, 1985, 354-355,368,377-379; McQuay, H. et al., BMJ (1995) 311: 1047-1052; Zakrzewska, J.M. et al., Pain (1997) 73: 233-230; Yu et al., "Simultaneous Delivery of Valproic Acid and Glycine to the Brain", Neuropath., 1991, 15(1): 37; "Milacemide", Drugs of the Future, 1984, 9(8): 587-588; and "Milacemide", Drugs of the Future, 1984, 9(8): 775. EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in | | | | отн | ER | DO | CUI | ME | NTS (Includ | ing Author, Title, Date. | Pertinent P | ages, Etc.) | | |
| Bialer et al., "Pharmacokinetics of a Valpromide Isomer, Valnoctamide, in Healthy Subjects", Eur. J. Clin. Pharmacol 1990,38:289-291; Buzzi et al., "The Antimigraine Drug, Sumatriptan (GR43175), Selectively Blocks Neurogenic Plasma Extravasation from Blood Vessels in Dura Mater", Brit. J. Pharmacol., 1990, 99: 202-206; Granneman et al., "Aspects of the Metabolism of Valproic Acid", Chem. Abstracts, 1984, 101(17): 143458; Granneman, "Aspects of the Metabolism of Valproic Acid", Xenobiotica, 1984, 14(5): 375-387; Hadad et al., "Pharmacokinetic Analysis of Ester Prodrugs of Valproic Acid," J. Pharm. Sci., 1992, 81(10): 1047-1050; Hansen, H.C., Southern Medical Journal (1999) 92(7):642-649; Haj-Yehia et al., "Structure-Pharmacokinetic Relationships in a Series of Valpromide Derivatives with Antiepilepti Activity", Pharm. Research, 1989, 6(8): 683-689; Kim et al., "An Experimental Model for Peripheral Neuropathy Produced by Segmental Spinal Nerve Ligation in the Rat J.M. Pain, 1992, 50: 355-363; March, Advanced Organic Chemistry, 3rd Edition, 1985, 354-355,368,377-379; McQuay, H. et al., BMJ (1995) 311: 1047-1052; Magnus, L., Epilepsia (1999) 40(Suppl. 6): S66-S72; Zakrzewska, J.M. et al., Pain (1997) 73: 233-230; Yu et al., "Simultaneous Delivery of Valproic Acid and Glycine to the Brain", Neuropath., 1991, 15(1): 37; "Milacemide", Drugs of the Future, 1984, 9(8): 587-588; and "Milacemide", Drugs of the Future, 1984, 9(8): 587-588; and "Milacemide", Drugs of the Future, 1984, 9(8): 587-588; and "Milacemide", Drugs of the Future, 1984, 9(8): 587-588; and "Milacemide", Drugs of the Future, 1984, 9(8): 587-588; and "Milacemide", Drugs of the Future, 1984, 9(8): 587-588; and "Milacemide", Drugs of the Future, 1984, 9(8): 587-588; and "Milacemide", Drugs of the Future, 1984, 9(8): 587-589; and "Milacemide", Drugs of the Future, 1984, 9(8): 587-589; and "Milacemide", Drugs of the Future, 1984, 9(8): 587-589; and "Milacemide", Drugs of the Future, 1984, 9(8): 587-589; and "Milacemide", Drugs of the Future, 19 | /SH/ | | Re-ex | amin | atio | n ce | rtifi | cate | of U.S. Pater | nt No. 4,913,906 (Exhibit | 1); | | | |
| Buzzi et al., "The Antimigraine Drug, Sumatriptan (GR43175), Selectively Blocks Neurogenic Plasma Extravasation from Blood Vessels in Dura Mater", Brit. J. Pharmacol., 1990, 99: 202-206; Granneman et al., "Aspects of the Metabolism of Valproic Acid", Chem. Abstracts, 1984, 101(17): 143458; Granneman, "Aspects of the Metabolism of Valproic Acid", Xenobiotica, 1984, 14(5): 375-387; Hadad et al., "Pharmacokinetic Analysis of Ester Prodrugs of Valproic Acid," J. Pharm. Sci., 1992, 81(10): 1047-1050; Hansen, H.C., Southern Medical Journal (1999) 92(7):642-649; Haj-Yehia et al., "Structure-Pharmacokinetic Relationships in a Series of Valpromide Derivatives with Antiepilepti Activity", Pharm. Research, 1989, 6(8): 683-689; Kim et al., "An Experimental Model for Peripheral Neuropathy Produced by Segmental Spinal Nerve Ligation in the Rat J.M. Pain, 1992, 50: 355-363; March, Advanced Organic Chemistry, 3 rd Edition, 1985, 354-355,368,377-379; McQuay, H. et al., BMJ (1995) 311: 1047-1052; Magnus, L., Epilepsia (1999) 40(Suppl. 6): S66-S72; Zakrzewska, J.M. et al., Pain (1997) 73: 233-230; Yu et al., "Simultaneous Delivery of Valproic Acid and Glycine to the Brain", Neuropath., 1991, 15(1): 37; "Milacemide", Drugs of the Future, 1984, 9(8): 587-588; and "Milacemide", Drugs of the Future, 1991, 16(8): 775. EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in | | | | | | | acok | inet | ics of a Valpro | omide Isomer, Valnoctamid | le, in Healthy | Subjects", Eu | r. J. Clin. Ph | armacol. |
| Blood Vessels in Dura Mater", Brit. J. Pharmacol., 1990, 99: 202-206; Granneman et al., "Aspects of the Metabolism of Valproic Acid", Chem. Abstracts, 1984, 101(17): 143458; Granneman, "Aspects of the Metabolism of Valproic Acid", Xenobiotica, 1984, 14(5): 375-387; Hadad et al., "Pharmacokinetic Analysis of Ester Prodrugs of Valproic Acid," J. Pharm. Sci., 1992, 81(10): 1047- 1050; Hansen, H.C., Southern Medical Journal (1999) 92(7):642-649; Haj-Yehia et al., "Structure-Pharmacokinetic Relationships in a Series of Valpromide Derivatives with Antiepilepti Activity", Pharm. Research, 1989, 6(8): 683-689; Kim et al., "An Experimental Model for Peripheral Neuropathy Produced by Segmental Spinal Nerve Ligation in the Rat J.M. Pain, 1992, 50: 355-363; March, Advanced Organic Chemistry, 3 rd Edition, 1985, 354- 355,368,377-379; McQuay, H. et al., BMJ (1995) 311: 1047-1052; Magnus, L., Epilepsia (1999) 40(Suppl. 6): S66-S72; Zakrzewska, J.M. et al., Pain (1997) 73: 233-230; Yu et al., "Simultaneous Delivery of Valproic Acid and Glycine to the Brain", Neuropath., 1991, 15(1): 37; "Milacemide", Drugs of the Future, 1984, 9(8): 587-588; and "Milacemide", Drugs of the Future, 1984, 9(8): 587-588; and "Milacemide", Drugs of the Future, 1984, 9(8): 775. EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in | | | | | | | timi | erain | e Drug, Sumat | riptan (GR43175). Selectiv | vely Blocks N | eurogenic Plas | ma Extravasa | tion from |
| Granneman, "Aspects of the Metabolism of Valproic Acid", Xenobiotica, 1984, 14(5): 375-387; Hadad et al., "Pharmacokinetic Analysis of Ester Prodrugs of Valproic Acid," J. Pharm. Sci., 1992, 81(10): 1047- 1050 Hansen, H.C., Southern Medical Journal (1999) 92(7):642-649; Haj-Yehia et al., "Structure-Pharmacokinetic Relationships in a Series of Valpromide Derivatives with Antiepilept Activity", Pharm. Research, 1989, 6(8): 683-689; Kim et al., "An Experimental Model for Peripheral Neuropathy Produced by Segmental Spinal Nerve Ligation in the Rat J.M. Pain, 1992, 50: 355-363; March, Advanced Organic Chemistry, 3 rd Edition, 1985, 354- 355,368,377-379; McQuay, H. et al., BMJ (1995) 311: 1047-1052; Magnus, L., Epilepsia (1999) 40(Suppl. 6): S66-S72; Zakrzewska, J.M. et al., Pain (1997) 73: 233-230; Yu et al., "Simultaneous Delivery of Valproic Acid and Glycine to the Brain", Neuropath., 1991, 15(1): 37; "Milacemide", Drugs of the Future, 1984, 9(8): 587-588; and "Milacemide", Drugs of the Future, 1991, 16(8): 775. EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in | | | Blood | Ves | sels | in D | ura l | Mate | r', Brit. J. Ph | armacol., 1990, 99: 202-206 | ; | | | |
| Hadad et al., "Pharmacokinetic Analysis of Ester Prodrugs of Valproic Acid," J. Pharm. Sci., 1992, 81(10): 1047- Hansen, H.C., Southern Medical Journal (1999) 92(7):642-649; Haj-Yehia et al., "Structure-Pharmacokinetic Relationships in a Series of Valpromide Derivatives with Antiepilept Activity", Pharm. Research, 1989, 6(8): 683-689; Kim et al., "An Experimental Model for Peripheral Neuropathy Produced by Segmental Spinal Nerve Ligation in the Rat J.M. Pain, 1992, 50: 355-363; March, Advanced Organic Chemistry, 3rd Edition, 1985, 354- 355,368,377-379; McQuay, H. et al., BMJ (1995) 311: 1047-1052; Magnus, L., Epilepsia (1999) 40(Suppl. 6): S66-S72; Zakrzewska, J.M. et al., Pain (1997) 73: 233-230; Yu et al., "Simultaneous Delivery of Valproic Acid and Glycine to the Brain", Neuropath., 1991, 15(1): 37; "Milacemide", Drugs of the Future, 1984, 9(8): 587-588; and "Milacemide", Drugs of the Future, 1991, 16(8): 775. EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in | | | Grann | eman | et al | ۰, "۵ | spec | cts o | f the Metabolis | sm of Valproic Acid", Cher | n. Abstracts, | 1984, 101(17): | 143458; | |
| Hansen, H.C., Southern Medical Journal (1999) 92(7):642-649; Haj-Yehia et al., "Structure-Pharmacokinetic Relationships in a Series of Valpromide Derivatives with Antiepilepti Activity", Pharm. Research, 1989, 6(8): 683-689; Kim et al., "An Experimental Model for Peripheral Neuropathy Produced by Segmental Spinal Nerve Ligation in the Rat J.M. Pain, 1992, 50: 355-363; March, Advanced Organic Chemistry, 3 rd Edition, 1985, 354- 355,368,377-379; McQuay, H. et al., BMJ (1995) 311: 1047-1052; Magnus, L., Epilepsia (1999) 40(Suppl. 6): S66-S72; Zakrzewska, J.M. et al., Pain (1997) 73: 233-230; Yu et al., "Simultaneous Delivery of Valproic Acid and Glycine to the Brain", Neuropath., 1991, 15(1): 37; "Milacemide", Drugs of the Future, 1984, 9(8): 587-588; and "Milacemide", Drugs of the Future, 1991, 16(8): 775. EXAMINER /San Ming Hui/ DATE CONSIDERED 11/15/2007 *EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in | | | Granneman, "Aspects of the Metabolism of Valproic Acid", Xenobiotica, 1984, 14(5): 375-387; | | | | | | | | | | | |
| Hansen, H.C., Southern Medical Journal (1999) 92(7):642-649; Haj-Yehia et al., "Structure-Pharmacokinetic Relationships in a Series of Valpromide Derivatives with Antiepilepti Activity", Pharm. Research, 1989, 6(8): 683-689; Kim et al., "An Experimental Model for Peripheral Neuropathy Produced by Segmental Spinal Nerve Ligation in the Rat J.M. Pain, 1992, 50: 355-363; March, Advanced Organic Chemistry, 3 rd Edition, 1985, 354- 355,368,377-379; McQuay, H. et al., BMJ (1995) 311: 1047-1052; Magnus, L., Epilepsia (1999) 40(Suppl. 6): S66-S72; Zakrzewska, J.M. et al., Pain (1997) 73: 233-230; Yu et al., "Simultaneous Delivery of Valproic Acid and Glycine to the Brain", Neuropath., 1991, 15(1): 37; "Milacemide", Drugs of the Future, 1984, 9(8): 587-588; and "Milacemide", Drugs of the Future, 1991, 16(8): 775. EXAMINER /San Ming Hui/ DATE CONSIDERED 11/15/2007 *EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in | | | Hadad et al., "Pharmacokinetic Analysis of Ester Prodrugs of Valoroic Acid." J. Pharm. Sci., 1992, 81(10): 1047- 1050 | | | | | | | | | - 1050 | | |
| Haj-Yehia et al., "Structure-Pharmacokinetic Relationships in a Series of Valpromide Derivatives with Antiepilept Activity", Pharm. Research, 1989, 6(8): 683-689; Kim et al., "An Experimental Model for Peripheral Neuropathy Produced by Segmental Spinal Nerve Ligation in the Rat J.M. Pain, 1992, 50: 355-363; March, Advanced Organic Chemistry, 3rd Edition, 1985, 354- 355,368,377-379; McQuay, H. et al., BMJ (1995) 311: 1047-1052; Magnus, L., Epilepsia (1999) 40(Suppl. 6): S66-S72; Zakrzewska, J.M. et al., Pain (1997) 73: 233-230; Yu et al., "Simultaneous Delivery of Valproic Acid and Glycine to the Brain", Neuropath., 1991, 15(1): 37; "Milacemide", Drugs of the Future, 1984, 9(8): 587-588; and "Milacemide", Drugs of the Future, 1991, 16(8): 775. EXAMINER /San Ming Hui/ DATE CONSIDERED 11/15/2007 *EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in | - | - | | | | | | | | | | | | |
| Kim et al., "An Experimental Model for Peripheral Neuropathy Produced by Segmental Spinal Nerve Ligation in the Rat J.M. Pain, 1992, 50: 355-363; March, Advanced Organic Chemistry, 3 rd Edition, 1985, 354- 355,368,377-379; McQuay, H. et al., BMJ (1995) 311: 1047-1052; Magnus, L., Epilepsia (1999) 40(Suppl. 6): S66-S72; Zakrzewska, J.M. et al., Pain (1997) 73: 233-230; Yu et al., "Simultaneous Delivery of Valproic Acid and Glycine to the Brain", Neuropath., 1991, 15(1): 37; "Milacemide", Drugs of the Future, 1984, 9(8): 587-588; and "Milacemide", Drugs of the Future, 1991, 16(8): 775. EXAMINER /San Ming Hui/ DATE CONSIDERED 11/15/2007 *EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in | | | | | | | | | | | | iepileptic | | |
| J.M. Pain, 1992, 50: 355-363; March, Advanced Organic Chemistry, 3 rd Edition, 1985, 354- 355,368,377-379; McQuay, H. et al., BMJ (1995) 311: 1047-1052; Magnus, L., Epilepsia (1999) 40(Suppl. 6): S66-S72; Zakrzewska, J.M. et al., Pain (1997) 73: 233-230; Yu et al., "Simultaneous Delivery of Valproic Acid and Glycine to the Brain", Neuropath., 1991, 15(1): 37; "Milacemide", Drugs of the Future, 1984, 9(8): 587-588; and "Milacemide", Drugs of the Future, 1991, 16(8): 775. EXAMINER /San Ming Hui/ DATE CONSIDERED 11/15/2007 *EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in | | Activity", Pharm. Research, 1989, 6(8): 683-689; | | | | | | | | | | | | |
| March, Advanced Organic Chemistry, 3rd Edition, 1985, 354- 355,368,377-379; McQuay, H. et al., BMJ (1995) 311: 1047-1052; Magnus, L., Epilepsia (1999) 40(Suppl. 6): S66-S72; Zakrzewska, J.M. et al., Pain (1997) 73: 233-230; Yu et al., "Simultaneous Delivery of Valproic Acid and Glycine to the Brain", Neuropath., 1991, 15(1): 37; "Milacemide", Drugs of the Future, 1984, 9(8): 587-588; and "Milacemide", Drugs of the Future, 1991, 16(8): 775. EXAMINER /San Ming Hui/ DATE CONSIDERED 11/15/2007 *EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in | | | | | | | | | | pheral Neuropathy Produc | ed by Segmen | ital Spinal Ner | e Ligation in | the Rat" |
| McQuay, H. et al., BMJ (1995) 311: 1047-1052; Magnus, L., Epilepsia (1999) 40(Suppl. 6): S66-S72; Zakrzewska, J.M. et al., Pain (1997) 73: 233-230; Yu et al., "Simultaneous Delivery of Valproic Acid and Glycine to the Brain", Neuropath., 1991, 15(1): 37; "Milacemide", Drugs of the Future, 1984, 9(8): 587-588; and "Milacemide", Drugs of the Future, 1991, 16(8): 775. EXAMINER /San Ming Hui/ DATE CONSIDERED 11/15/2007 *EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in | | | Marci | <u>, ani</u> 1. Adv | ance | 2, 3 | rgani | ic Cl | nemistry, 3 rd E | dition, 1985, 354- 355,368. | 377-379: | | | |
| Zakrzewska, J.M. et al., Pain (1997) 73: 233-230; Yu et al., "Simultaneous Delivery of Valproic Acid and Glycine to the Brain", Neuropath., 1991, 15(1): 37; "Milacemide", Drugs of the Future, 1984, 9(8): 587-588; and "Milacemide", Drugs of the Future, 1991, 16(8): 775. EXAMINER /San Ming Hui/ DATE CONSIDERED 11/15/2007 *EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in | | | | | | | | | | | | | | , |
| Yu et al., "Simultaneous Delivery of Valproic Acid and Glycine to the Brain", Neuropath., 1991, 15(1): 37; "Milacemide", Drugs of the Future, 1984, 9(8): 587-588; and "Milacemide", Drugs of the Future, 1991, 16(8): 775. EXAMINER /San Ming Hui/ DATE CONSIDERED 11/15/2007 *EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in | | | | | | | | | | | | | | |
| "Milacemide", <u>Drugs of the Future</u> , 1984, 9(8): 587-588; and "Milacemide", <u>Drugs of the Future</u> , 1991, 16(8): 775. EXAMINER /San Ming Hui/ DATE CONSIDERED 11/15/2007 *EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in | ├ ─- ├ ─- | | | | | | | | | | | | | |
| *EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in | 1 | ļ | | | | | | | | | e Brain", Neu | ropath., 1991, | 15(1): 37; | |
| EXAMINER /San Ming Hui/ DATE CONSIDERED 11/15/2007 *EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in | lacksquare | | | | | | | | | | | | | |
| *EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | EXAMIN | ER / | _ | | | | | | | | 007 | | | |
| | *EXAMI | NER: I | nitial if o | itatior idered | cons | sider | ed, w | heth of th | er or not citation | n is in conformance with MPE | P 609: Draw li | ne through citat | ion if not in | |